Iterum Therapeutics Plc (ITRM) has released an update to notify the public and investors about the submission of matters to a vote of security holders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Iterum Therapeutics plc held an extraordinary general meeting on January 30, 2024, during which shareholders voted against a proposal that would have allowed the board of directors to issue an additional 5,000,000 ordinary shares for cash without the customary pre-emptive rights for existing shareholders. The proposal required a 75% affirmative vote but failed to achieve this threshold, with 3,139,498 votes for, 2,724,101 against, and 26,719 abstentions. There were no broker non-votes since the matter was deemed “routine” under NYSE rules.
For further insights into ITRM corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.